Baricitinib, an oral selective inhibitor of JAK1 and JAK2, improved pruritus and sleep loss when combined with TCSs in cases of moderate to severe AD, but its efficacy as a monotherapy is lacking. This evidence concerns the gene JAK1 and Alzheimer disease.